Celgene (Nasdaq: CELG) announced that data were presented from a phase 1b/2 study of ISTODAX (romidepsin) combined with cyclophosphamide, doxorubicin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE